S

Scilex Holding Co
NASDAQ:SCLX

Watchlist Manager
Scilex Holding Co
NASDAQ:SCLX
Watchlist
Price: 13.09 USD 7.3% Market Closed
Market Cap: 99.4m USD

SCLX's latest stock split occurred on Apr 15, 2025

The company executed a 1-for-35 stock split, meaning that for every 35 shares held, investors received 1 new share.

Before the split, SCLX traded at 0.1885 per share. Afterward, the share price was about 6.92.

The adjusted shares began trading on Apr 15, 2025. This was the only stock split in SCLX's history.

Last Splits:
Apr 15, 2025
1-for-35
Pre-Split Price
6.5975 0.1885
Post-Split Price
6.92
Before
After
Last Splits:
Apr 15, 2025
1-for-35

Scilex Holding Co
Stock Splits History

SCLX Stock Splits Timeline
Apr 15, 2025
Apr 15, 2025
Split 1-for-35
/0.028571428571429
Pre-Split Price
6.5975 0.1885
Post-Split Price
6.92
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Scilex Holding Co
Glance View

Market Cap
99.4m USD
Industry
Pharmaceuticals

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.

SCLX Intrinsic Value
Not Available
S
Back to Top